Aerobic exercise for neuropathy after ovarian-cancer chemotherapy

Evidence label: Promising secondary randomized signal · Clinical goal: reduce persistent chemotherapy-induced peripheral-neuropathy symptoms

Evidence at a glance

Population: 134 women with ovarian cancer who had received chemotherapy.
Intervention: six months of home moderate aerobic activity targeting 150 minutes weekly, with trainer telephone support.
Result: self-reported neuropathy improved by 1.6 points more than with attention control.

What was studied

This prespecified secondary analysis of the phase III WALC trial included 69 participants assigned to exercise and 65 to weekly health-education calls. Neuropathy was measured with the 0–44 FACT/GOG-Neurotoxicity scale.

What the evidence shows

Scores changed by −1.3 points (95% CI −2.3 to −0.2) with exercise and +0.4 (95% CI −0.8 to 1.5) with control: between-group difference −1.6 (95% CI −3.1 to −0.2; P=.03). Among 127 participants with baseline symptoms, the difference was −2.0 points. The clinical-importance threshold for this scale was not established.

This is supportive-care or rehabilitation evidence. It does not show that the intervention treats cancer, prevents recurrence or prolongs survival unless a record explicitly identifies a validated cancer-control endpoint.

Limits and uncertainty

Neuropathy was a secondary outcome, was self-reported rather than examined objectively, and more than 90% of participants were non-Hispanic White. The study mainly addresses symptoms after chemotherapy and cannot establish prevention during treatment. No exercise adverse events were reported.

Safety and practical context

Neuropathy can impair balance and foot sensation. Walking plans may need footwear review, fall-risk assessment, lower-impact options and supervision. New weakness, rapidly progressive symptoms or falls need clinical review.

Questions for the care team

Is my neuropathy stable enough for a walking program?
Should balance, footwear or assistive devices be assessed first?
How will benefit be measured without mistaking normal fluctuation for recovery?

Sources

Literature searched: October 16, 2026 · Record appraised: October 16, 2026

Educational evidence summary, not personal medical advice. Research regimens describe what was studied; they are not personal prescribing instructions and should not replace cancer treatment or individualized supportive care.